Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
NCT07685535Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2026
- Primary completion
- Jun 2028
01
Overview
A Phase 2 trial of toripalimab, lenvatinib, gemcitabine, oxaliplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhongshan Hospital, Fudan University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
toripalimablenvatinibgemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07685535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07685535.